^
Association details:
| Biomarker: | FLT3 wild-type |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | PHI-101 (FLT3 inhibitor, Chk2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4283 PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial
Published date:
11/02/2023
Excerpt:
In this first-in-human, phase Ia/Ib trial of PHI-101, 92% of FLT3-wild or -mutated AML pts showed clinical responses even after having previously been treated with otherFLT3 inhibitors. More notably, 100% of pts who had relapsed after prior gilteritinib treatment showed clinical responses.
Trial ID:
